• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases
      • All News Releases
      • All Public Company
      • English-only


      • News Releases Overview
      • Multimedia Gallery
      • All Multimedia
      • All Photos
      • All Videos


      • Multimedia Gallery Overview
      • Trending Topics
      • All Trending Topics


  • Business & Money
      • Auto & Transportation
      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation


      • Auto & Transportation Overview
      • Business Technology
      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors


      • Business Technology Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television


      • Entertain­ment & Media Overview
      • Financial Services & Investing
      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Stock Offering
      • Stock Split
      • Venture Capital


      • Financial Services & Investing Overview
      • General Business
      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News


      • General Business Overview
  • Science & Tech
      • Consumer Technology
      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications


      • Consumer Technology Overview
      • Energy & Natural Resources
      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities


      • Energy & Natural Resources Overview
      • Environ­ment
      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters


      • Environ­ment Overview
      • Heavy Industry & Manufacturing
      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco


      • Heavy Industry & Manufacturing Overview
      • Telecomm­unications
      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications


      • Telecomm­unications Overview
  • Lifestyle & Health
      • Consumer Products & Retail
      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys


      • Consumer Products & Retail Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television


      • Entertain­ment & Media Overview
      • Health
      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine


      • Health Overview
      • Sports
      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories


      • Sports Overview
      • Travel
      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry


      • Travel Overview
  • Policy & Public Interest
      • Policy & Public Interest
      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy


      • Policy & Public Interest Overview
  • People & Culture
      • People & Culture
      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women


      • People & Culture Overview
      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO

      Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Policy & Public Interest
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • People & Culture
    • People & Culture
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Diabeloop introduces an automated management solution for highly unstable diabetes

DBL-hu, a medical device dedicated to the autonomous management of highly unstable diabetes1, obtained its CE mark less than a year after the launch of its pivotal clinical trial began

Diabeloop Logo (PRNewsfoto/Diabeloop)

News provided by

Diabeloop

Dec 01, 2020, 09:07 ET

Share this article

Share this article


PARIS, Dec. 1, 2020 /PRNewswire/ --

Diabeloop announced today that it has obtained CE marking for its innovative and adjustable technological solution: DBL-hu.
DBL-hu improves glycemic control and satisfaction for people living with a form of diabetes that is very complex to manage.
Diabeloop expands its position in therapeutic artificial intelligence, following CE marking of DBLG1 in 2018.

innovation diabetes Diabeloop

Highly unstable diabetes: people in therapeutic distress

While innovative treatments for the 250,000 people living with Type 1 diabetes in France, 2.0 million in Europe and 1.5 million in the USA are helping to improve their daily lives, highly unstable diabetes - also called labile diabetes - remains complex to manage and balance with the solutions currently available on the market.

Hélène Lefebvre, Project Leader for DBL-hu at Diabeloop, explains the genesis of this project: "A very small proportion of people with Type 1 diabetes have what is called highly unstable diabetes. There aren't two identical reasons in two different people; the researchers do not understand, to date, what creates this physiological upheaval and what leads these patients to have sudden variations between very high and very low blood sugar levels, even more so than other people with Type 1 diabetes. Several diabetologists have told us that DBLG1 System from Diabeloop is working well and that something should be done for these patients. So we started the DBL-hu project keeping in mind that we were going to have to adapt the algorithm for these people with very complex physiologies to stabilize."

DBL-hu: an adapted and individualized response to a true need

Today, few alternatives are available to people living with highly unstable Type 1 diabetes. An improved implantable insulin pump will not be available in France for a few years. Surgical options exist, with pancreas transplantation and islet transplantation. However, these procedures do not offer an absolute guarantee of success and require heavy immunosuppressive treatment. Individuals who participated in the DBL-hu clinical study had a contraindication to islet transplantation.

The option offered by Diabeloop with its closed-loop system - DBL-hu - allows patients and their physicians to consider a less invasive and flexible solution. With this device, they can enjoy a more stable daily life, a lighter mental load, reduced risk of hypoglycemic episodes and much better diabetes control.

Erik Huneker, co-founder and CEO of Diabeloop says:
"With Professor Pierre-Yves Benhamou, we discussed this problem and quickly decided to launch this clinical trial on a few patients, in an attempt to improve their lives. By customizing the device according to the patients, we quickly obtained very positive results, i.e. a real "life solution". A diabetologist who had heard of DBL-hu explained to us that he had a patient for whom nothing worked. He wanted to offer her this treatment, except that we could not include her in the clinical study, we did not have the CE mark... We then asked the ANSM (French Health Regulation Authority) for authorization to equip this patient on a compassionate basis, an exceptional exemption for a medical device. In view of our excellent results, we obtained this authorization to include the patient in a regulatory framework. At the same time, we submitted our CE marking file which was going to solve the problem of these patients with highly unstable T1D."

Extremely promising clinical trial results

Diabeloop, which has developed a medical device for people living with Type 1 diabetes, took an interest in these patients in therapeutic distress and quickly launched a clinical trial that resulted in CE marking in less than a year.

During the clinical trial, 7 patients were randomized. The use of the DBL-hu system was associated with a gain in time spent in the ideal glycemic range (70-180 mg/dl) of 29.8% in absolute value (73.3% of the time versus 43.5%), and also improved glucose variability, satisfaction score and perceived frequency of hypoglycemia.

These results demonstrate a significant medical breakthrough in highly unstable Type 1 diabetes.

Professor Pierre-Yves Benhamou shed light on the success of the clinical study that led DBL-hu to CE marking:
"By analyzing the very good results of the closed-loop on T1D patients, we launched this clinical trial by adjusting the closed-loop with settings that take into account these profiles of patients with more unstable metabolism. These patients have abrupt variations, they can go up to 300mg/dl in a few seconds and suddenly go down to 50mg/dl. We included 7 patients, theoretical islet transplant candidates, in this study. Engineers added nearly 3 times more settings to DBLG1 to adapt it to highly unstable diabetes. Thanks to these settings, blood glucose levels were much more stable, with some patients almost doubling time in range, from 35% / 40% to more than 70%. Patients are much more confident thanks to the DBL-hu system, managed with their diabetologist, the settings are done quickly and the results are effective from the very first days, blood glucose levels are much more stable. We have confirmed this during the 4 sequences performed on these targets, in random order: with the DBL-hu system or a standard treatment and the order of passage drawn at random; switching from the open-loop to the closed-loop improved the results and conversely, switching from the closed-loop to the open-loop deteriorated them."

Patient testimonials during the clinical trial:

"To give you a closed-loop evaluation of the past month, less subjective than my patient opinion, here is the evolution of my glycated hemoglobin level: before the study 8.1% in April 2019 then 8.2% in August 2019 and... 7.28% this Saturday! I am so happy!"

"I have noticed since the beginning of the closed-loop that my quality of life has increased dramatically, as the system clearly allows the management of hypo and hyperglycemia. The result is that I no longer have hypo during the night, so I am really less tired and the management of hyper has the same effect."

Following the rapid CE marking of DBL-hu, the next step is to obtain reimbursement that would allow the device to be offered to healthcare teams and people living with highly unstable diabetes.

For more information on Diabeloop: https://www.diabeloop.com/

About Diabeloop
Diabeloop's mission: to relieve people living with Type 1 diabetes from dozens of daily therapeutic decisions and reduce their heavy mental burden. Initially conceived from a medical research project, Diabeloop was created in 2015 by Dr. Guillaume Charpentier, now Chief Medical Officer, and Erik Huneker who have co-managed the company with Marc Julien since 2016. This complementary management team works with experienced partners, CEA-Leti (a research laboratory) and CERITD (a French research team of diabetologists).

In November 2018, the DBLG1 System, Diabeloop's first medical device for automated diabetes management, obtained CE marking. A second round of financing of 31 million euros concluded in November 2019 to speed up the international commercial rollout of the DBLG1 iController and support an ambitious R&D program.

Today, Diabeloop gathers the personality, the passion and the skills of 80 talented individuals who work hard to improve the quality of life for every person living with Type 1 diabetes.

1Diabetes Obesity and Metabolism, October 2020:  Benhamou PY, Lablanche S, Vambergue A, Doron M, Franc S, Charpentier G. Highly unstable type 1 diabetes eligible for islet transplantation can be managed with closed-loop insulin delivery. A series of N-of-1 randomised controlled trials.

Press contact:
Diabeloop
Stéphanie JÉGU
[email protected]
[email protected]

SOURCE Diabeloop

Modal title

Also from this source

Diabeloop integrates the Accu-Chek Insight insulin pump from...


Diabeloop appoints Catherine Dunand Chairman of the Board...

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Medical Equipment
  • Medical Pharmaceuticals
  • Biotechnology
  • Artificial Intelligence

    Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

    Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

    About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement

    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom

    My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision


Products


About


My Services
  • All News Releases
  • Online Member Center
  • ProfNet℠
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2021 Cision US Inc.